Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2016’, provides an overview of the Amyotrophic Lateral Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis

The report reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Amyotrophic Lateral Sclerosis therapeutics and enlists all their major and minor projects

The report assesses Amyotrophic Lateral Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

AB Science SA

Aestus Therapeutics Inc

Anavex Life Sciences Corp

Angion Biomedica Corp

Apodemus AB

Apogenix GmbH

Apotex Inc

ArmaGen Inc

BioCrea GmbH

Biogen Inc

Biohaven Pharmaceutical Holding Company Limited

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Calico LLC

Catabasis Pharmaceuticals Inc

Cellceutix Corp

Chronos Therapeutics Ltd

ContraVir Pharmaceuticals Inc

Corcept Therapeutics Inc

Curatis Pharma GmbH

Cytokinetics Inc

Daval International Ltd

Edison Pharmaceuticals Inc

Eisai Co Ltd

Ensemble Therapeutics Corp

Evotec AG

F. Hoffmann-La Roche Ltd

Flex Pharma, Inc.

FPRT Bio Inc

Gemac

Genentech Inc

Genervon Biopharmaceuticals LLC

GeNeuro SA

GenKyoTex SA

Glialogix Inc

Grifols SA

Herantis Pharma Plc

ImStar Therapeutics Inc.

InFlectis BioScience

Ionis Pharmaceuticals Inc

Italfarmaco SpA

Jeil Pharmaceutical Co Ltd

Kadimastem Ltd

Karyopharm Therapeutics Inc

KineMed Inc

Kringle Pharma Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Lascco SA

Lead Discovery Center GmbH

M's Science Corp

Maas Biolab

Mallinckrodt Plc

MedDay SA

MeiraGTx Limited

miCure Therapeutics Ltd.

miRagen Therapeutics Inc

MitoDys Therapeutics Limited

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

Neuraltus Pharmaceuticals Inc

Neurimmune Holding AG

Neurotec Pharma SL

Neurotune AG

Orion Oyj

Orphazyme ApS

Pharnext SA

Plex Pharmaceuticals Inc

Prevacus Inc

Primary Peptides, Inc.

ProMIS Neurosciences Inc

Q Therapeutics Inc

ReceptoPharm Inc

Regenesance BV

reMYND NV

Saneron CCEL Therapeutics Inc

SciFluor Life Sciences LLC

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Symic Biomedical Inc

Teva Pharmaceutical Industries Ltd

Thera Neuropharma Inc

Treeway BV

Valeant Pharmaceuticals International Inc

ViroMed Co Ltd

VivaCell Biotechnology Espana SL

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

Yooyoung Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Amyotrophic Lateral Sclerosis Overview 8

Therapeutics Development 9

Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 11

Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 20

Amyotrophic Lateral Sclerosis - Pipeline Products Glance 22

Amyotrophic Lateral Sclerosis - Products under Development by Companies 26

Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 35

Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 38

Amyotrophic Lateral Sclerosis - Therapeutics Assessment 128

Drug Profiles 150

Amyotrophic Lateral Sclerosis - Discontinued Products 474

Amyotrophic Lateral Sclerosis - Product Development Milestones 476

Appendix 488

List of Tables

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016 29

Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 32

Number of Products under Development by Companies, H2 2016 (Contd..1) 33

Number of Products under Development by Companies, H2 2016 (Contd..2) 34

Number of Products under Development by Companies, H2 2016 (Contd..3) 35

Number of Products under Development by Companies, H2 2016 (Contd..4) 36

Number of Products under Development by Companies, H2 2016 (Contd..5) 37

Number of Products under Development by Companies, H2 2016 (Contd..6) 38

Number of Products under Development by Companies, H2 2016 (Contd..7) 39

Number of Products under Investigation by Universities/Institutes, H2 2016 40

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 41

Comparative Analysis by Late Stage Development, H2 2016 42

Comparative Analysis by Clinical Stage Development, H2 2016 43

Comparative Analysis by Early Stage Development, H2 2016 44

Comparative Analysis by Unknown Stage Development, H2 2016 45

Products under Development by Companies, H2 2016 46

Products under Development by Companies, H2 2016 (Contd..1) 47

Products under Development by Companies, H2 2016 (Contd..2) 48

Products under Development by Companies, H2 2016 (Contd..3) 49

Products under Development by Companies, H2 2016 (Contd..4) 50

Products under Development by Companies, H2 2016 (Contd..5) 51

Products under Development by Companies, H2 2016 (Contd..6) 52

Products under Development by Companies, H2 2016 (Contd..7) 53

Products under Development by Companies, H2 2016 (Contd..8) 54

Products under Investigation by Universities/Institutes, H2 2016 55

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 56

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 57

Amyotrophic Lateral Sclerosis – Pipeline by 2-BBB Medicines BV, H2 2016 58

Amyotrophic Lateral Sclerosis – Pipeline by AB Science SA, H2 2016 59

Amyotrophic Lateral Sclerosis – Pipeline by Aestus Therapeutics Inc, H2 2016 60

Amyotrophic Lateral Sclerosis – Pipeline by Anavex Life Sciences Corp, H2 2016 61

Amyotrophic Lateral Sclerosis – Pipeline by Angion Biomedica Corp, H2 2016 62

Amyotrophic Lateral Sclerosis – Pipeline by Apodemus AB, H2 2016 63

Amyotrophic Lateral Sclerosis – Pipeline by Apogenix GmbH, H2 2016 64

Amyotrophic Lateral Sclerosis – Pipeline by Apotex Inc, H2 2016 65

Amyotrophic Lateral Sclerosis – Pipeline by ArmaGen Inc, H2 2016 66

Amyotrophic Lateral Sclerosis – Pipeline by BioCrea GmbH, H2 2016 67

Amyotrophic Lateral Sclerosis – Pipeline by Biogen Inc, H2 2016 68

Amyotrophic Lateral Sclerosis – Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 69

Amyotrophic Lateral Sclerosis – Pipeline by BioHealthonomics Inc, H2 2016 70

Amyotrophic Lateral Sclerosis – Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 71

Amyotrophic Lateral Sclerosis – Pipeline by Calico LLC, H2 2016 72

Amyotrophic Lateral Sclerosis – Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 73

Amyotrophic Lateral Sclerosis – Pipeline by Cellceutix Corp, H2 2016 74

Amyotrophic Lateral Sclerosis – Pipeline by Chronos Therapeutics Ltd, H2 2016 75

Amyotrophic Lateral Sclerosis – Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 76

Amyotrophic Lateral Sclerosis – Pipeline by Corcept Therapeutics Inc, H2 2016 77

Amyotrophic Lateral Sclerosis – Pipeline by Curatis Pharma GmbH, H2 2016 78

Amyotrophic Lateral Sclerosis – Pipeline by Cytokinetics Inc, H2 2016 79

Amyotrophic Lateral Sclerosis – Pipeline by Daval International Ltd, H2 2016 80

Amyotrophic Lateral Sclerosis – Pipeline by Edison Pharmaceuticals Inc, H2 2016 81

Amyotrophic Lateral Sclerosis – Pipeline by Eisai Co Ltd, H2 2016 82

Amyotrophic Lateral Sclerosis – Pipeline by Ensemble Therapeutics Corp, H2 2016 83

Amyotrophic Lateral Sclerosis – Pipeline by Evotec AG, H2 2016 84

Amyotrophic Lateral Sclerosis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 85

Amyotrophic Lateral Sclerosis – Pipeline by Flex Pharma, Inc., H2 2016 86

Amyotrophic Lateral Sclerosis – Pipeline by FPRT Bio Inc, H2 2016 87

Amyotrophic Lateral Sclerosis – Pipeline by Gemac, H2 2016 88

Amyotrophic Lateral Sclerosis – Pipeline by Genentech Inc, H2 2016 89

Amyotrophic Lateral Sclerosis – Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 90

Amyotrophic Lateral Sclerosis – Pipeline by GeNeuro SA, H2 2016 91

Amyotrophic Lateral Sclerosis – Pipeline by GenKyoTex SA, H2 2016 92

Amyotrophic Lateral Sclerosis – Pipeline by Glialogix Inc, H2 2016 93

Amyotrophic Lateral Sclerosis – Pipeline by Grifols SA, H2 2016 94

Amyotrophic Lateral Sclerosis – Pipeline by Herantis Pharma Plc, H2 2016 95

Amyotrophic Lateral Sclerosis – Pipeline by ImStar Therapeutics Inc., H2 2016 96

Amyotrophic Lateral Sclerosis – Pipeline by InFlectis BioScience, H2 2016 97

Amyotrophic Lateral Sclerosis – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 98

Amyotrophic Lateral Sclerosis – Pipeline by Italfarmaco SpA, H2 2016 99

Amyotrophic Lateral Sclerosis – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 100

Amyotrophic Lateral Sclerosis – Pipeline by Kadimastem Ltd, H2 2016 101

Amyotrophic Lateral Sclerosis – Pipeline by Karyopharm Therapeutics Inc, H2 2016 102

Amyotrophic Lateral Sclerosis – Pipeline by KineMed Inc, H2 2016 103

Amyotrophic Lateral Sclerosis – Pipeline by Kringle Pharma Inc, H2 2016 104

Amyotrophic Lateral Sclerosis – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 105

Amyotrophic Lateral Sclerosis – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 106

Amyotrophic Lateral Sclerosis – Pipeline by Lascco SA, H2 2016 107

Amyotrophic Lateral Sclerosis – Pipeline by Lead Discovery Center GmbH, H2 2016 108

Amyotrophic Lateral Sclerosis – Pipeline by M's Science Corp, H2 2016 109

Amyotrophic Lateral Sclerosis – Pipeline by Maas Biolab, H2 2016 110

Amyotrophic Lateral Sclerosis – Pipeline by Mallinckrodt Plc, H2 2016 111

Amyotrophic Lateral Sclerosis – Pipeline by MedDay SA, H2 2016 112

Amyotrophic Lateral Sclerosis – Pipeline by MeiraGTx Limited, H2 2016 113

Amyotrophic Lateral Sclerosis – Pipeline by miCure Therapeutics Ltd., H2 2016 114

Amyotrophic Lateral Sclerosis – Pipeline by miRagen Therapeutics Inc, H2 2016 115

Amyotrophic Lateral Sclerosis – Pipeline by MitoDys Therapeutics Limited, H2 2016 116

Amyotrophic Lateral Sclerosis – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 117

Amyotrophic Lateral Sclerosis – Pipeline by Neuralstem Inc, H2 2016 118

Amyotrophic Lateral Sclerosis – Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016 119

Amyotrophic Lateral Sclerosis – Pipeline by Neurimmune Holding AG, H2 2016 120

Amyotrophic Lateral Sclerosis – Pipeline by Neurotec Pharma SL, H2 2016 121

Amyotrophic Lateral Sclerosis – Pipeline by Neurotune AG, H2 2016 122

Amyotrophic Lateral Sclerosis – Pipeline by Orion Oyj, H2 2016 123

Amyotrophic Lateral Sclerosis – Pipeline by Orphazyme ApS, H2 2016 124

Amyotrophic Lateral Sclerosis – Pipeline by Pharnext SA, H2 2016 125

Amyotrophic Lateral Sclerosis – Pipeline by Plex Pharmaceuticals Inc, H2 2016 126

Amyotrophic Lateral Sclerosis – Pipeline by Prevacus Inc, H2 2016 127

Amyotrophic Lateral Sclerosis – Pipeline by Primary Peptides, Inc., H2 2016 128

Amyotrophic Lateral Sclerosis – Pipeline by ProMIS Neurosciences Inc, H2 2016 129

Amyotrophic Lateral Sclerosis – Pipeline by Q Therapeutics Inc, H2 2016 130

Amyotrophic Lateral Sclerosis – Pipeline by ReceptoPharm Inc, H2 2016 131

Amyotrophic Lateral Sclerosis – Pipeline by Regenesance BV, H2 2016 132

Amyotrophic Lateral Sclerosis – Pipeline by reMYND NV, H2 2016 133

Amyotrophic Lateral Sclerosis – Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 134

Amyotrophic Lateral Sclerosis – Pipeline by SciFluor Life Sciences LLC, H2 2016 135

Amyotrophic Lateral Sclerosis – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 136

Amyotrophic Lateral Sclerosis – Pipeline by Spherium Biomed SL, H2 2016 137

Amyotrophic Lateral Sclerosis – Pipeline by Symic Biomedical Inc, H2 2016 138

Amyotrophic Lateral Sclerosis – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 139

Amyotrophic Lateral Sclerosis – Pipeline by Thera Neuropharma Inc, H2 2016 140

Amyotrophic Lateral Sclerosis – Pipeline by Treeway BV, H2 2016 141

Amyotrophic Lateral Sclerosis – Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 142

Amyotrophic Lateral Sclerosis – Pipeline by ViroMed Co Ltd, H2 2016 143

Amyotrophic Lateral Sclerosis – Pipeline by VivaCell Biotechnology Espana SL, H2 2016 144

Amyotrophic Lateral Sclerosis – Pipeline by Voyager Therapeutics Inc, H2 2016 145

Amyotrophic Lateral Sclerosis – Pipeline by WAVE Life Sciences Ltd, H2 2016 146

Amyotrophic Lateral Sclerosis – Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016 147

Assessment by Monotherapy Products, H2 2016 148

Assessment by Combination Products, H2 2016 149

Number of Products by Stage and Target, H2 2016 151

Number of Products by Stage and Mechanism of Action, H2 2016 159

Number of Products by Stage and Route of Administration, H2 2016 167

Number of Products by Stage and Molecule Type, H2 2016 169

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2016 483

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..1), H2 2016 484

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..2), H2 2016 485

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..3), H2 2016 486

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..4), H2 2016 487

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..5), H2 2016 488

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..6), H2 2016 489

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..7), H2 2016 490

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..8), H2 2016 491

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..9), H2 2016 492

Amyotrophic Lateral Sclerosis – Dormant Projects (Contd..10), H2 2016 493

Amyotrophic Lateral Sclerosis – Discontinued Products, H2 2016 494

Amyotrophic Lateral Sclerosis – Discontinued Products (Contd..1), H2 2016 495

List of Figures

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016 29

Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Investigation by Universities/Institutes, H2 2016 40

Comparative Analysis by Late Stage Development, H2 2016 42

Comparative Analysis by Clinical Stage Development, H2 2016 43

Comparative Analysis by Early Stage Products, H2 2016 44

Assessment by Monotherapy Products, H2 2016 148

Assessment by Combination Products, H2 2016 149

Number of Products by Top 10 Targets, H2 2016 150

Number of Products by Stage and Top 10 Targets, H2 2016 150

Number of Products by Top 10 Mechanism of Actions, H2 2016 158

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 158

Number of Products by Top 10 Routes of Administration, H2 2016 166

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 166

Number of Products by Top 10 Molecule Types, H2 2016 168

Number of Products by Stage and Top 10 Molecule Types, H2 2016 168

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports